The effect of intravitreal bevacizumab treatment on choroidal metastasis of colon adenocarcinoma—case report

Cj, Lin; Ли, Х.; Jf, Hwang; Chen, SN

doi:10.1038/eye.2009.257

Cited by 35 publications

(38 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4][5][6][7][8][9] Our outcomes in two cases of adenocarcinoma of caecum, one breast carcinoma, and one adenocarcinoma of lung do not replicate this finding. Difference in pathologies do not explain this, as good effects have been described treating metastases from the same primaries: colon, 4 breast, 2,5,8 and lung.…”

Section: Discussioncontrasting

confidence: 37%

See 1 more Smart Citation

Failure of intravitreal bevacizumab in the treatment of choroidal metastasis

Maudgil

Sears

Rundle

et al. 2015

Eye

View full text Add to dashboard Cite

Background Metastasis to choroid is the most common intraocular malignancy, arising most frequently from carcinoma of breast in women and lung in men. Recent case reports have described successful use of intravitreal bevacizumab to achieve local control of such tumours. Materials and methods Five cases of choroidal metastases from varying primaries: breast, lung, and colon were treated with intravitreal bevacizumab, and tumour response observed and documented with serial photographs and B-scans. Results Four of the five tumours were seen to progress despite intravitreal bevacizumab treatment. Conclusions Intravitreal bevacizumab as the primary treatment of choroidal metastases is not recommended and should not delay more effective alternative treatments.

show abstract

Section: Discussioncontrasting

confidence: 37%

“…We used bevacizumab 1.25 mg in 0.05 ml, prepared from a vial commercially available for intravitreal use (Avastin). Previous reports have used bevacizumab 2.5 mg 3,5,6,9 and others 4 mg. 2,4 The most recent cohort published 7 used bevacizumab 1.25 mg and report regression in 3 cases with comparable pathologies.…”

Section: Discussionmentioning

confidence: 99%

Failure of intravitreal bevacizumab in the treatment of choroidal metastasis

Maudgil

Sears

Rundle

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…The authors demonstrated that this treatment was best for small, circumscribed uveal metastases in the absence of an exudative retinal detachment. 21 This discovery is not a surprise as the drug bevacizumab (Avastin) was originally developed for the systemic treatment of gastrointestinal cancer. The injections may be repeated on a 4-6 weekly basis similar to the treatment of choroidal neovascular membranes in macular degeneration.…”

Section: Treatmentmentioning

confidence: 99%

“…This has been demonstrated for adenocarcinoma of the lung and colon metastatic to the uveal tract. 20,21 A dose of up to 4 mg of bevacizumab was administered; 21 however, 1.25 mg also appears to be effective. The authors demonstrated that this treatment was best for small, circumscribed uveal metastases in the absence of an exudative retinal detachment.…”

Section: Treatmentmentioning

confidence: 99%

Ocular metastases

Cohen

2012

Eye

View full text Add to dashboard Cite

The eye is a rare site for disseminated malignancy because of the absence of a lymphatic system. Metastases to the ocular structures occur by haematogenous spread and therefore the parts of the eye with the best vascular supply are most likely to be affected. Many patients with Stage 4 carcinomatosis (distal metastatic spread) already have a history of a previous primary cancer. However, this is not always the case for lung cancer as this can metastasise early to the uveal tract and therefore the ophthalmologist may be the first to discover the presence of terminal metastatic disease. Broadly speaking, treatment options are focused on improving the patients' quality of life if visual acuity is threatened. Long-term side effects of treatment need to be considered as systemic cancer treatments and therefore patient life expectancy is improving. In this manuscript, presented at the Cambridge symposium 2012, the diagnosis and challenges involved in the management of ocular metastases are presented.

show abstract

“…3 We would also tend to believe that CM from other solid tumors may also have variable degrees of responsiveness to IV-Bev, as has been documented in the literature, including those published in your journal. [4][5][6] In conclusion, while we fully agree with that use of IV-Bev for CM should not delay initiation of other treatment modalities, we strongly believe that this implies using the most appropriate form of systemic therapy in combination with IV-Bev rather than not using IV-Bev at all.…”

mentioning

confidence: 86%